AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

• Status: Completed
• Trial end date: 2004-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The study tests the safety and efficacy of axitinib in patients who have the hematologic disease of Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study tests patients who have poor prognosis before entering the study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Axitinib

Criteria

Inclusion Criteria:

• Poor prognosis AML or MDS

• Histological confirmation of diagnosis

• White blood cell count less than or equal to 30,000/mm3

• Adequate hepatic and renal function documented within 14 days prior to registration

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

• No evidence of preexisting uncontrolled hypertension

• Not a suitable candidate for chemotherapy

• No prior systemic chemotherapy treatment for AML or MDS or treatment with an anti-angiogenesis agent

Exclusion Criteria:

• Patients must not have exclusion criteria.

• Candidate for chemotherapy

• Patients with AML M3 (acute promyelocytic leukemia)

• Conditions that might confound the evaluation of safety or efficacy or increase patient risk.